3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Conditions
Ovarian Neoplasms
86
Breast Neoplasms
68
Triple Negative Breast Neoplasms
32
Prostatic Neoplasms
32
Fallopian Tube Neoplasms
25
Neoplasms
23
Neoplasm Metastasis
21
Pancreatic Neoplasms
18
Endometrial Neoplasms
18
Small Cell Lung Carcinoma
13
Carcinoma, Ovarian Epithelial
11
Carcinoma, Non-Small-Cell Lung
10
Stomach Neoplasms
9
Sarcoma
9
Recurrence
9
Lung Neoplasms
9
Fanconi Anemia, Complementation Group D1
9
Squamous Cell Carcinoma of Head and Neck
8
Glioma
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Glioblastoma
7
Colorectal Neoplasms
6
Metastatic Castration-resistant Prostate Cancer
5
Lymphoma, Non-Hodgkin
5
Cholangiocarcinoma
5
Carcinoma, Renal Cell
5
Uterine Cervical Neoplasms
4
Urinary Bladder Neoplasms
4
Solid Tumors
4
Osteosarcoma
4
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Carboplatin
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Sunitinib
2
Standard of Care
2
Riluzole
2
Radiation Dose Hypofractionation
2
Prednisone
2
Pluvicto
2
Mitomycin
2
LDP-02
2
Infliximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Neoplasms
×
olaparib
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled
NCT04566952
2020-10-30
ANLOLA
Jiangsu Cancer Institute & Hospital
Phase 2
Unknown
68 enrolled